Toggle Main Menu Toggle Search

Open Access padlockePrints

Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy

Lookup NU author(s): Dr Nduka OkwoseORCiD, Dr Guy MacGowanORCiD, Professor Djordje JakovljevicORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic cardiomyopathy. Thirty Wistar Kyoto rats, 10 healthy (control) and 20 rats with confirmed hypertension-induced hypertrophic cardiomyopathy (HpCM), were used for this study. The HpCM group was further subdivided into untreated and sacubitril/valsartan-treated groups. Myocardial structure and function were assessed using echocardiography, Langendorff’s isolated heart experiment, blood sampling and qualitative polymerase chain reaction. Echocardiographic examinations revealed protective effects of sacubitril/valsartan by improving left ventricular internal diameter in systole and diastole and fractional shortening. Additionally, sacubitril/valsartan treatment decreased systolic and diastolic blood pressures in comparison with untreated hypertensive rats. Moreover, sacubitril/valsartan treatment reduced oxidative stress and apoptosis (reduced expression of Bax and Cas9 genes) compared to untreated rats. There was a regular histomorphology of cardiomyocytes, interstitium, and blood vessels in treated rats compared to untreated HpCM rats which expressed hypertrophic cardiomyocytes, with polymorphic nuclei, prominent nucleoli and moderately dilated interstitium. In experimental model of hypertension-induced hypertrophic cardiomyopathy, sacubitril/valsartan treatment led to improved cardiac structure, haemodynamic performance, and reduced oxidative stress and apoptosis. Sacubitril/valsartan thus presents as a potential therapeutic strategy resulted in hypertension-induced hypertrophic cardiomyopathy.

Publication metadata

Author(s): Jeremic J, Govoruskina N, Bradic J, Milosavljevic I, Srejovic I, Zivkovic V, Jeremic N, Nikolic Turnic T, Tanaskovic I, Bolevich S, Jakovljevic V, Bolevich S, Zivanovic MN, Okwose N, Seklic D, Milivojevic N, Grujic J, Velicki L, MacGowan G, Jakovljevic DG, Filipovic N

Publication type: Article

Publication status: Published

Journal: Molecular and Cellular Biochemistry

Year: 2023

Volume: 478

Pages: 2645–2656

Online publication date: 30/03/2023

Acceptance date: 24/02/2023

ISSN (print): 0300-8177

ISSN (electronic): 1573-4919

Publisher: Springer


DOI: 10.1007/s11010-023-04690-7


Altmetrics provided by Altmetric